MRS 1845

CAS : 544478-19-5

Ref. 3D-UWA47819

Informations sur le produit

• Nom: MRS 1845
• Synonymes: 3-Pyridinecarboxylic acid, 4-[3-(3-dioxaziridinyl)phenyl]-1,4-dihydro-5-(3-hydroxy-1-oxopropyl)-2,6-dimethyl-1-(2-propyn-1-yl)-, methyl ester, Methyl 4-[3-(dioxaziridin-3-yl)phenyl]-5-(3-hydroxypropanoyl)-2,6-dimethyl-1-(prop-2-yn-1-yl)-1,4-dihydropyridine-3-carboxylate

Description

MRS 1845 is a cytostatic drug that inhibits the growth of cancer cells by inhibiting mitochondrial membrane potential, which leads to an increase in intracellular calcium levels and the activation of apoptosis. MRS 1845 has been shown to inhibit the growth of cancer cells in vitro and in vivo. This drug also has clinical relevance for treatment of chronic myeloid leukemia (CML) and breast cancer. MRS 1845 inhibits the production of protein kinase C, which is an effector protein involved in cell proliferation.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 398.41 g/mol
• Formule: C₂₁H₂₂N₂O₆
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder